Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update

STATEN ISLAND, N.Y., Aug. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2024. Highlights of the second quarter ended June 30, 2024, or in some cases shortly thereafter, include:In April 2024, we completed a successful End-of-Phase 2 Clin ...